Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Acromegaly
Interventions
DRUG

Lanreotide autogel 120 mg

12 months

Trial Locations (27)

3000

ERASMUS MC Rotterdam, Rotterdam

3508

UMC Utrecht, Utrecht

13385

Hôpital de la Timone, Marseille

20357

ENDOC Zentrum für Endokrine Tumoren und Praxis für Endokrinologie, Andrologie und medikamentöse Tumortherapie, Hamburg

20520

The Turku University Central Hospital, Turku

34303

Cerrahpasa Medical Facility, Istanbul

45122

Universitatsklinikum Essen, Essen

60590

Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt

80336

Medizinische Klinik Innenstadt, München

91054

Friedrich-Alexander University, Erlangen

94010

CHU Henri Mondor, Créteil

98125

"AOU Policlinico G. Martino Messina", Messina

B2650

University Hospital Antwerpen, Edegem

128 08 Praha 2

Všeobecná fakultní nemocnice, Karlova Univerzita, Prague

9 FIN-00290

Helsinki University Center Hospital, Helsinki

76230 Cedex

Hopital De Bois Guillaume, Bois-Guillaume

38043 Cedex

CHU Grenoble Albert Michallon, Grenoble

Unknown

CHRU Lille Hopital Claude Huriez, Lille

CHU de Reims, Hopital Robert Debré, Reims

69677 Bron Cedex

Groupement Hospitalier Est, Lyon

94275 Cedex

Hôpital Bicêtre, Paris

33604 Cedex

Hopital Haut Leveque, Pessac

5 80131

Università Federico II di Napoli, Dipartimento di Endocrinologia Molecolare e Clinicae Oncologia, Napoli

00168

Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, U.O.C. di Endocrinologia, Roma

AB25 2ZN

27/28 Aberdeen Royal Infirmary, Aberdeen

M20 4BX

Christie Hospital, Manchester

PL6 8DH

Derriford Hospital, Plymouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY